CIRIUM
6.1.2022 09:21:06 CET | Business Wire | Press release
Aviation analytics firm Cirium, reveals that December was the busiest month in 2021 for flights globally, totaling 2.43 million, however the total number of flights canceled globally between December 24, 2021, and January 3, 2022, was 59,240, some 2.4%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105006010/en/
The number of cancelations over this period is the most cancelations in December for the past decade, six times more than the cancelations in 2019 and two and half times more than 2020. A total of 20,500 flights were canceled in the first three days of the new year.
The big four US airlines, including American Airlines, Delta Air Lines, Southwest Airlines and United Airlines, canceled nearly 7,040 flights over this period.
The cancelations being driven by the surging cases of the Omicron variant of COVID-19 and other operational challenges (including winter weather). Airlines rapidly canceled flights due to staff shortages across crew and ground operations.
Pre-Omicron, global flights flown increased 1.5% week-over-week (December 11-17, 2021). However, global flights are now down 5% compared to the week prior, following the impact of Omicron.
There are large variances between the regions, with the US, Europe and North Atlantic down 9-10%, China up 6%, while Asia-Pacific and Middle East are flat.
“Flight disruptions affect airlines and airports differently – it depends on the availability and flexibility of equipment and resources in place to react quickly. Those that plan more conservatively will minimize their operational disruptions. Cirium monitors the level of disruption by measuring completion factor of flights and their on-time performance,” said Jeremy Bowen CEO at Cirium.
“Cirium’s recent On-Time Performance Review shows how some airlines have focused on their operations to reduce the impact on passengers. For example, Delta Air Lines completed 99.8% of their flights from June to December 2021 and All Nippon Airways, the winner of the Global airline category in Cirium’s Review had a completion factor of 99.2%.”
Consideration is given to the carriers with high volumes of flights. For example, American Airlines flew the most flights in 2021 – around 1,850,050 – and still, its flights arrived 80.47% on time. The carrier did have trouble reinstating flight volumes after more than a year of deeply depressed demand yet completed 97.5% of its flights.
Hartsfield-Jackson Atlanta International Airport (ATL), the major hub for Delta Air Lines, was the busiest airport based on departing flights with 336,890 this year. Despite handling the most flights, it ranked 15th in on-time performance of the Top 20 Global airports.
Amsterdam Airport (AMS) was the busiest airport for international flights in 2021, with a total of 123,070 departing flights, however, it didn’t make the Top 20 airport rankings for on-time performance. Airports have experienced many variables this year in deploying comprehensive pandemic protocols, optimizing the reconciliation and collection of fees and services, and optimizing staffing.
Cirium’s On-Time Performance Review is the industry standard for airlines and airports operational performance. Cirium resumed reporting in June 2021, as flight volumes returned, with regular monthly updates that help gauge the industry’s performance in getting passengers from point A to point B, on time. Cirium’s on-time performance analysis is based on flight data from over 600 sources of real-time flight information.
Click here to download the complimentary On-Time Performance Review 2021.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insights, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105006010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
